Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

NCT04055844 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: Decitabine
DRUG: Ruxolitinib
DRUG: Donor Lymphocyte Infusion (DLI)

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]